Bioventus Inc. Stock

Equities

BVS

US09075A1088

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2024-04-26 EDT 5-day change 1st Jan Change
3.98 USD -2.21% Intraday chart for Bioventus Inc. -11.16% -24.48%
Sales 2024 * 528M 722M Sales 2025 * 562M 768M Capitalization 254M 347M
Net income 2024 * -47M -64.24M Net income 2025 * -32M -43.74M EV / Sales 2024 * 1.1 x
Net Debt 2024 * 328M 448M Net Debt 2025 * 273M 373M EV / Sales 2025 * 0.94 x
P/E ratio 2024 *
-8.04 x
P/E ratio 2025 *
-14.5 x
Employees 970
Yield 2024 *
-
Yield 2025 *
-
Free-Float 67.01%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.21%
1 week-11.16%
Current month-23.46%
1 month-22.87%
3 months-11.95%
6 months+20.97%
Current year-24.48%
More quotes
1 week
3.95
Extreme 3.95
4.60
1 month
3.95
Extreme 3.95
5.30
Current year
3.95
Extreme 3.95
6.08
1 year
0.86
Extreme 0.86
6.08
3 years
0.80
Extreme 0.7999
19.94
5 years
0.80
Extreme 0.7999
19.94
10 years
0.80
Extreme 0.7999
19.94
More quotes
Managers TitleAgeSince
Chief Executive Officer - 01-09
Director of Finance/CFO 55 22-03-20
Compliance Officer 62 -
Members of the board TitleAgeSince
Chairman 70 16-06-29
Director/Board Member 63 19-12-31
Director/Board Member 68 16-06-29
More insiders
Date Price Change Volume
24-04-26 3.98 -2.21% 128,404
24-04-25 4.07 -1.93% 71,893
24-04-24 4.15 -3.71% 118,230
24-04-23 4.31 +0.47% 99,318
24-04-22 4.29 -4.24% 144,156

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm

More quotes
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.98 USD
Average target price
8 USD
Spread / Average Target
+101.01%
Consensus